Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lupin Categorically Denies Sell-off Talks Amid Speculation Of $1 Billion Valuation For India Business

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Could Lupin Ltd. be the next to sell off its India business to a multinational drug company? Sources report that Lupin is considering selling its India business for a deal valued at as much as $1 billion, and several market analysts in India say the question is not without merit
Advertisement

Related Content

Eli Lilly Ropes In Lupin For A Big Push For Its Insulin Brands In India
Eli Lilly Ropes In Lupin For A Big Push For Its Insulin Brands In India
Size Is Rewarded When Fostering Brand In India, But Pricing Has To Be Right: Elsevier Business Intelligence Webinar
A Closer Look: Why Are Indian Pharma Promoters Diversifying Into Other Sectors?
India's Health Minister Hits Out At Buyouts By Foreign Drug Makers; Are Investment Restrictions In The Cards?
Piramal Deal Done, Abbott's India Plunge May Fetch Big Returns, But Integration Challenges, Growth Momentum Critical
Piramal Deal Done, Abbott's India Plunge May Fetch Big Returns, But Integration Challenges, Growth Momentum Critical
Advertisement
UsernamePublicRestriction

Register

SC078516

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel